Ruairi J Mackenzie is a Senior Science Writer for Technology Networks. With a focus on diverse scientific topics, Ruairi covers a wide range of subjects including neuroscience, microbiology, genetics, and emerging technologies. His articles aim to provide readers with in-depth and accessible information on the latest advancements and discoveries in the scientific world.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ruairi's articles predominantly focus on scientific and healthcare-related topics, particularly in the fields of neuroscience, medical research, microbiology, and health. With a strong emphasis on citing data in his coverage, Ruairi would likely be interested in receiving pitches from experts who can provide credible and evidence-based insights into the latest developments or studies within these areas.
Given Ruairi’s frequent coverage of scientific findings and healthcare breakthroughs, he may be responsive to pitches offering access to researchers involved in groundbreaking studies or clinical trials. Additionally, sources with expertise in interpreting complex scientific data for broader audiences could also find success pitching to him.
While Ruari does not have a specified geographic focus, it is evident that his reporting covers global advances within the realm of science and healthcare without specific regional limitations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ruairi J Mackenzie
Hello and welcome to the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis. Here, we’ll highlight some of the most significant psychedelic industry news from the past month, including important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.
In hospital settings, multidrug-resistant organisms (MDRO) are a major threat to patient safety.
By: Ruairi J Mackenzie
Now, a new study details an ingenious task that explores how rats weigh up complex economic decisions.
An analysis of Maryland ketamine advertisers has suggested that their websites and marketing materials are awash with false and misleading claims about the drug's addictiveness, side effects and approval status.
By: Ruairi J Mackenzie
Bacterial vaginosis, like many women’s health conditions, has a serious but underappreciated impact. In vaginosis, the vagina’s natural microbiome – the community of microorganisms that call it home – becomes disrupted. The condition remained poorly understood – until now.
A community-led study has revealed a trove of genomic data for over 100 cultivars of “magic” mushrooms. The research details how domestication has reduced the genetic diversity of the mushroom.
By: Ruairi J Mackenzie
A world-first cell atlas has opened a window into the complexity of the mammalian brain. The map details more than 5,000 cell-type clusters in the mouse brain and marks out their location.
A new study suggests that Alzheimer’s proteins may spread in a “prion-like” fashion. So, what is a prion, and how does this finding change what we know about Alzheimer's?
After the twists and turns of discovering a new drug molecule, pharma companies still face a mighty challenge: delivering their candidate drugs to the area of the body where they are needed.
"As you progress in your career as a scientist, it's impossible to stagnate. You stay young, creative and excited about your work." – Dr. Kanaka Rajan.
(833) 317-6278 
